Skip to content

Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum

Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02244996
Enrollment
50
Registered
2014-09-19
Start date
2014-11-30
Completion date
2017-11-30
Last updated
2019-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinitis Pigmentosa

Keywords

Retinitis pigmentosa, Lycium barbarum, Antioxidation, Visual field, Electroretinogram

Brief summary

Objectives: To study the immediate effect and the persistent effect of Lycium barbarum (LB) treatment on retinal functions, especially the cone function, and retinal structure in patients with retinitis pigmentosa (RP) Design: Randomised controlled double-masked trial Setting: Primary Care clinical trial Participants: 120 RP subjects will be recruited from Ophthalmology department at The University of Hong Kong and the Retina Hong Kong. Interventions: Subjects will be randomly allocated to LB (treated with LB granules) or control (treated with placebo) groups for 1 year. After the 1st year, both groups will stop the treatment and all subjects will also have the same eye exam in 6-month period for the 2nd year. Main outcome measures: The primary outcome is the total sensitivity scores of 30-2 & 60-4 programmes of Humphrey Visual Field Analysis (HVFA). The secondary outcomes are the b-wave amplitudes of Full-field Electroretinogram (ffERG) responses, the amplitudes of direct component and induced component of Multifocal Electroretinogram (mfERG), and the ETDRS visual acuity.

Detailed description

The study was a randomized controlled trial with a double-masked, placebo-controlled design. All the subjects were randomly allocated into either LB (treatment) group or placebo (control) group. All the eligible subjects had the eye examination, including VA using the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, refractions, tonometry, external and internal ocular health assessments, and fundus photo-documentation. Three additional tests were conducted to investigate the functional and structural changes in the RP patients, including Ganzfeld Electroretinogram, Humphrey Visual Field Analyser (Zeiss, Dublin, USA) and Spectral-domain Optical Coherent Tomography (SD-OCT) (Heidelberg Engineering, USA).

Interventions

DIETARY_SUPPLEMENTLycium Barbarum

Traditional Chinese Herbs

DIETARY_SUPPLEMENTPlacebo

Placebo

Sponsors

The University of Hong Kong
CollaboratorOTHER
The Hong Kong Polytechnic University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Ocular conditions: * Retinitis pigmentosa; * best corrected VA LogMAR 0.20 or better; * Humphrey Visual Field Analysis (HVFA) 30-2 total mean defect \> or = 250 Decibel; * Intra-ocular pressure (IOP) \<21 mmHg; * van Herrick ratio \< or = 0.5; * no other ocular diseases Dietary conditions: * Fruit and vegetable intake \<10 servings/day; * spinach or kale intake \< or = serving/day; * dietary lutein intake \< or = 5.4mg/day; * no intake of cod liver oil or omega-3 capsules; * dietary Lycium barbarum intake \< or =10 fruits/week; * supplement intake \< or = 5000 IU/day of Vit. A and \< or = 30 IU/day of Vit. E; * alcoholic consumption \< or = 3 beverages/day

Exclusion criteria

* BMI \> 40; * intake of any anticoagulants (especially Warfarin), * pregnant or planning to be pregnant; * smoking; * other clinically significant systemic diseases, eg. diabetes, liver disease and heart disease

Design outcomes

Primary

MeasureTime frameDescription
ETDRS Visual Acuity (High Contrast)12 monthsThe high contrast visual acuity will be measured at the time point of baseline and 12 months. Visual acuity is to measure the eye's ability to resolve fine detail with full refractive error correction. The change of acuity (sec of arc) between 12-month time point and baseline will be provided to show the effect of interventions. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum.

Secondary

MeasureTime frameDescription
Visual Field Sensitivity12 monthsHumphrey Visual Field Analyser will be used to measure the brightness sensitivity across the central 30 degree visual field at time point of baseline and 12 months. Visual field is to measure the size of the field of view and the sensitivity of the corresponding locations of the field of view. The change of sensitivity (dB) between 12-month time point and baseline will be provide to show the effects of interventions. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum
Amplitudes of Flash Electroretinogram12 monthsThe cone responses from electroretinogram will be measured at the time point of baseline and 12 months. The cone response is related to the activity of the cone photoreceptor under light stimulation. The change of cone response b-wave amplitude (uV) between 12-month and baseline will be provided to show the effect of interventions. The b-wave amplitude is to measure the magnitude of electrical responses of cone cells in the retina. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum.
Implicit Times of Flash Electroretinogram12 monthsThe cone responses from electroretinogram will be measured at the time point of baseline and 12 months. The cone response is related to the activity of the cone photoreceptor under light stimulation. The change of cone response b-wave implicit time (ms) between 12-month and baseline will be provided to show the effect of interventions. The b-wave implicit time is to measure the physiological changes of cone cells in the retina. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum.

Countries

Hong Kong

Participant flow

Recruitment details

Recruited from a retinal disease patient association, Retina Hong Kong, and the Optometry Clinic at The Hong Kong Polytechnic University

Pre-assignment details

All the eligible subjects had the eye examination, including VA (ETDRS) charts, refractions, tonometry, external and internal ocular health assessments, fundus photo-documentation, Ganzfeld Electroretinogram, Humphrey Visual Field Analyser and Spectral-domain Optical Coherent Tomography

Participants by arm

ArmCount
Lycium Barbarum
Daily Lycium Barbarum dosage: 10g of granules for 12 months Lycium Barbarum: Traditional Chinese Herbs
23
Placebo
Placebo Placebo: Placebo
19
Total42

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLack of Efficacy26

Baseline characteristics

CharacteristicLycium BarbarumPlaceboTotal
Age, Continuous50.4 years
STANDARD_DEVIATION 12.2
48.4 years
STANDARD_DEVIATION 9.3
49.4 years
STANDARD_DEVIATION 10.9
Region of Enrollment
Hong Kong
23 participants19 participants42 participants
Sex: Female, Male
Female
14 Participants14 Participants28 Participants
Sex: Female, Male
Male
9 Participants5 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 230 / 19
other
Total, other adverse events
0 / 230 / 19
serious
Total, serious adverse events
0 / 230 / 19

Outcome results

Primary

ETDRS Visual Acuity (High Contrast)

The high contrast visual acuity will be measured at the time point of baseline and 12 months. Visual acuity is to measure the eye's ability to resolve fine detail with full refractive error correction. The change of acuity (sec of arc) between 12-month time point and baseline will be provided to show the effect of interventions. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum.

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Lycium BarbarumETDRS Visual Acuity (High Contrast)-0.02 log unitStandard Deviation 0.09
PlaceboETDRS Visual Acuity (High Contrast)0.11 log unitStandard Deviation 0.17
Secondary

Amplitudes of Flash Electroretinogram

The cone responses from electroretinogram will be measured at the time point of baseline and 12 months. The cone response is related to the activity of the cone photoreceptor under light stimulation. The change of cone response b-wave amplitude (uV) between 12-month and baseline will be provided to show the effect of interventions. The b-wave amplitude is to measure the magnitude of electrical responses of cone cells in the retina. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum.

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Lycium BarbarumAmplitudes of Flash Electroretinogram2.75 uVStandard Deviation 9.17
PlaceboAmplitudes of Flash Electroretinogram-4.00 uVStandard Deviation 7.38
Secondary

Implicit Times of Flash Electroretinogram

The cone responses from electroretinogram will be measured at the time point of baseline and 12 months. The cone response is related to the activity of the cone photoreceptor under light stimulation. The change of cone response b-wave implicit time (ms) between 12-month and baseline will be provided to show the effect of interventions. The b-wave implicit time is to measure the physiological changes of cone cells in the retina. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum.

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Lycium BarbarumImplicit Times of Flash Electroretinogram-1.33 msecStandard Deviation 5.03
PlaceboImplicit Times of Flash Electroretinogram-1 msecStandard Deviation 6.69
Secondary

Visual Field Sensitivity

Humphrey Visual Field Analyser will be used to measure the brightness sensitivity across the central 30 degree visual field at time point of baseline and 12 months. Visual field is to measure the size of the field of view and the sensitivity of the corresponding locations of the field of view. The change of sensitivity (dB) between 12-month time point and baseline will be provide to show the effects of interventions. The changes of the treatment group will be compared with the changes of the placebo group to illustrate the treatment effect of Lycium Barbarum

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
Lycium BarbarumVisual Field Sensitivity0.32 dBStandard Deviation 2.93
PlaceboVisual Field Sensitivity-0.16 dBStandard Deviation 0.94

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026